Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | TRANSCEND-CLL-004: lisocabtagene maraleucel in CLL

Tanya Siddiqi • 16 Jul 2020
EHA 2020
Acalabrutinib CAR-T Ibrutinib Lisocabtagene maraleucel Venetoclax
TRANSCEND-CLL-004

Tanya Siddiqi, MD, of the City of Hope National Medical Center, Duarte, CA, discusses results from the Phase I/II TRANSCEND-CLL-004 (NCT03331198) study, evaluating the safety and efficacy of the Juno CAR T-cell, lisocabtagene maraleucel, in chronic lymphocytic leukemia (CLL) patients pre-treated with a BTK inhibitor. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Tanya Siddiqi

Updates on T-cell engagers and CARs in CLL: liso-cel, novel agents, and resistance mechanisms
12:13
Updates on T-cell engagers and CARs in CLL: liso-cel, novel agents, and resistance mechanisms
Alexey Danilov et al. • 25 Apr 2026
Expanding the CAR platform for NHL
11:30
Expanding the CAR platform for NHL
Catherine Bollard et al. • 28 Sep 2025
CAR-T in CLL: updates from the TRANSCEND-CLL-004 trial and when to choose CAR-T for these patients
2:19
CAR-T in CLL: updates from the TRANSCEND-CLL-004 trial and when to choose CAR-T for these patients
Tanya Siddiqi • 7 Feb 2025
Future directions for CAR-T therapy in CLL: the potential of combining CAR T-cells with other agents
1:29
Future directions for CAR-T therapy in CLL: the potential of combining CAR T-cells with other agents
Tanya Siddiqi • 7 Feb 2025

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals